logo
Products
Services
Resources
Selection Guides
About
FITC Anti-human CD11a Antibody
TS-1/22.1.1.13
TS-1/22.1.1.13 is an anti-human monoclonal antibody that targets the CD11a antigen. CD11a (also known as ITGAL or LFA-1α chain) is a 170 - 180 kD transmembrane glycoprotein that is found on the surface of cells such as NK cells, T cells, macrophages and B cells. CD11a plays a role in vital cellular pathways, namely, the integrin-mediated signaling pathway. Also, it has been closely linked to key biological processes like cell-cell adhesion, especially leukocyte cell-cell adhesion. From a research standpoint, it is of biological interest due to its association with vital macromolecules/ligands like ICAM-1 and CD18. CD11a is a fairly uncommon antibody target, with a little more than 3000 publications in the last decade. Even still, CD11a is frequently used in flow cytometry applications as a phenotypic marker for differentiation of cell types, specifically in the study of costimulatory molecules, neuroinflammation and innate immunity. This antibody was purified through affinity chromatography and conjugated to FITC (ex/em = 491/516 nm). It is compatible with the 488 nm laser and 527/32 nm bandpass filter (for example, as in the BD FACSVerse™).
product image
CatalogSize
Price
Quantity
101151I0100 tests
Price
101151I1500 tests
Price
 
Antibody properties

Other namesLFA-1A, Integrin aL, ITGAL
CloneTS-1/22.1.1.13
HostMouse
IsotypeIgG1
ReactivityHuman
ApplicationFlow Cytometry (FACS), Fluorescence Imaging
Spectral properties

Absorbance (nm)488
Correction factor (280 nm)0.35
Extinction coefficient (cm -1 M -1)
73000
Excitation (nm)491
Emission (nm)516
Quantum yield
0.92
Usage and storage

Intended useResearch Use Only (RUO)
Contact us

Telephone
Fax
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Request quotationRequest
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Page updated on August 20, 2026